

# Long-term Follicular Cancer

ENDORAMA 2/21/2014

#### **HPI**

- 66 year old male
- 1970's Left thyroid lobectomy for benign disease
- 2003 Right completion lobectomy and central neck dissection for follicular thyroid carcinoma
- Treated twice with RAI (12/03, 8/04)
- Neck Ultrasound shoed a right-sided neck node in the thyroid bed
  - Ethanol ablation

#### HPI

October 2013 – new palpable cervical node

Neck ultrasound – node around the location of the isthmus

MEDICINE

### **PMHx**

## PSurgHx


- HTN
- Arthritis
- Gout
- Hyperlipidemia

As above

### Surgery

- Pretracheal LN was superficial and adjacent to the strap muscles
  - Confirmed by frozen section to be thyroid cancer
- Complete right central lymph node dissection
  - Thyroid remnant with scar tissue overlying right
     RLN

- 82 patients for review
  - 49 patients from original study
  - 33 patients found in our pathology bank
- Original study followed patients for average of 10.7 years
  - 18% recurrence rate (disease in neck or distant more than 12 months from original surgery)
  - 16% thyroid specific mortality
  - 8/9 patients with recurrence died of thyroid specific complications
  - Recurrence was not seen past 13 years









Fig. 5. Survival is shown for patients under age 45 yr (0) or over age 45 yr (1).


Demographics	Mean (years)	Range (years)
Average Age at Dx	41 ± 16	14-79
Average Age at Death	69 ± 17	32-94
Years of Death followup	20.8 ± 13.1	0.1-48
Years of Recurrence followup	19.6 ± 13.4	0.2-48

### All Cause Mortality Pre-Path




Median time to death 36 years. 39.4% survival at 48 years

### Thyroid-related Deaths Pre-path



FCC: 71.8% disease-free survival at 48 years

### Recurrence Pre-Path




FCC: 77.9% recurrence-free

at 48 years

### Path-Review

- Of the 54 specimens (out of 82) that were reviewed
  - 24 PTC/FV-PTC
  - 14 FCC (Follicular cell carcinoma)
  - 4 HCC (Hurthle cell carcinoma)
  - 12 benign (FTA, HCA, fibrosis)

Demographics	Mean/Median (years)	Range (years)	
Average age at diagnosis	43 ± 15	16-74	
Average age at death	67 ± 18	32-94	
Years to Death FU (median)	21	0.1-48	
Years to Recurrence FU (median)	21	0.2-48	




Median time to Death from all causes:


FCC: 16 years HCC: 10 years

FCC: 24.5% at 32

years




FCC: 50.2% survival at 32 years HCC: 66.7% survival at 34 years



FCC: 50.9% recurrence-free at 32 years HCC: 71.4% recurrence-free at 34 years

#### Path Review

- 54 patients reviewed
  - 24 PTC/FV-PTC
  - 9 minimally invasive FCC/HCC
  - 2 widely invasive FCC/HCC
  - 7 metastatic or poorly differentiated FCC/HCC
  - 12 benign




Median time to Death from all causes:


MI: 27 years WI: 1 month

Met/poor diff: 9

years



Median time to
Death from
thyroid cancer:
WI: 1 month
Met/poor diff: 11
years




Median time to recurrence:

WI: 4 months


Met/poor diff: 10

years


	Category	Median Survival Time (years)	Survival/Recurrence- Free	Follow-up Time (years)
	Pre-Path FCC All Cause Mortality	36	39.4%	48
	Pre-Path FCC Thyroid Mortality	TE UN	71.8%	48
	Pre-Path FCC Recurrence	THI	77.9%	48
	Post-Path FCC All Cause Mortality	16	24.5%	32
	Post-Path FCC Thyroid Mortality	LEDI	52.2%	32
	Post-Path FCC Recurrence		50.9%	32



Log rank p=0.002



Log rank p=0.0016



Log rank p=0.0179

FCC&HCC	Median survival at	At 48 years
THE	UNIVE	RSITY OF
All-cause survival	36 years	39%
Thyroid Specific survival		71%
Recurrence free survival		78%